Contrasting of BioDelivery Sciences International Inc. (BDSI) and Ra Pharmaceuticals Inc. (NASDAQ:RARX)

BioDelivery Sciences International Inc. (NASDAQ:BDSI) and Ra Pharmaceuticals Inc. (NASDAQ:RARX) compete against each other in the Biotechnology sector. We will contrast them and contrast their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioDelivery Sciences International Inc. 5 5.28 N/A -0.61 0.00
Ra Pharmaceuticals Inc. 26 483.31 N/A -1.92 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for BioDelivery Sciences International Inc. and Ra Pharmaceuticals Inc.


Table 2 shows BioDelivery Sciences International Inc. and Ra Pharmaceuticals Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
BioDelivery Sciences International Inc. 0.00% -118.3% -34.9%
Ra Pharmaceuticals Inc. 0.00% -47% -43.5%


BioDelivery Sciences International Inc.’s Current Ratio is 2.9 while its Quick Ratio is 2.6. On the competitive side is, Ra Pharmaceuticals Inc. which has a 20.1 Current Ratio and a 20.1 Quick Ratio. Ra Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to BioDelivery Sciences International Inc.

Analyst Recommendations

In next table is shown BioDelivery Sciences International Inc. and Ra Pharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
BioDelivery Sciences International Inc. 0 0 5 3.00
Ra Pharmaceuticals Inc. 0 0 1 3.00

BioDelivery Sciences International Inc.’s upside potential currently stands at 53.85% and an $7.4 consensus price target. On the other hand, Ra Pharmaceuticals Inc.’s potential upside is 90.66% and its consensus price target is $49. The results provided earlier shows that Ra Pharmaceuticals Inc. appears more favorable than BioDelivery Sciences International Inc., based on analyst opinion.

Institutional & Insider Ownership

Institutional investors held 60.9% of BioDelivery Sciences International Inc. shares and 99.9% of Ra Pharmaceuticals Inc. shares. Insiders held 3.3% of BioDelivery Sciences International Inc. shares. On the other hand, insiders held about 0.6% of Ra Pharmaceuticals Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
BioDelivery Sciences International Inc. -5.36% -20.73% -21.4% -17.56% 40% 0.27%
Ra Pharmaceuticals Inc. -0.76% 2.81% 56.87% 72.27% 210.02% 87.03%

For the past year BioDelivery Sciences International Inc. has weaker performance than Ra Pharmaceuticals Inc.


Ra Pharmaceuticals Inc. beats on 6 of the 8 factors BioDelivery Sciences International Inc.

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive (BEMA) drug delivery technology, which consists of a small, erodible polymer film for application to the buccal mucosa. It offers ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and BELBUCA, a buprenorphine buccal film for the treatment of chronic pain. The company also develops Buprenorphine Depot Injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. It has a licensing and development agreement with Endo Pharmaceuticals, Inc.; Evonik Corporation; Collegium Pharmaceutical, Inc.; and Meda AB. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The companyÂ’s peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), as well as for the treatment of other debilitating complement-mediated diseases, including refractory generalized myasthenia gravis (rMG) and lupus nephritis (LP). The companyÂ’s preclinical testing products include Factor D inhibition for age-related macular degeneration and geographic atrophy, as well as for Orphan renal dense deposit and C3 glomerulonephritis; Oral C5 inhibitor for PNH, rMG, LN, and central nervous system (CNS) diseases; and C1s inhibition for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.